Cipher Pharmaceuticals Competitors

Cipher Pharmaceuticals (TSE:CPH) and WeedMD (CVE:WMD) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, valuation, analyst recommendations, dividends and institutional ownership.

Earnings & Valuation

This table compares Cipher Pharmaceuticals and WeedMD's top-line revenue, earnings per share and valuation.

Cipher Pharmaceuticals has higher earnings, but lower revenue than WeedMD. WeedMD is trading at a lower price-to-earnings ratio than Cipher Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Cipher Pharmaceuticals and WeedMD's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of current recommendations for Cipher Pharmaceuticals and WeedMD, as reported by MarketBeat.

WeedMD has a consensus target price of C$0.58, suggesting a potential upside of 85.19%. Given WeedMD's higher possible upside, analysts plainly believe WeedMD is more favorable than Cipher Pharmaceuticals.

Summary

Cipher Pharmaceuticals beats WeedMD on 5 of the 8 factors compared between the two stocks.

Cipher Pharmaceuticals (TSE:CPH) and Acerus Pharmaceuticals (TSE:ASP) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, dividends, risk and institutional ownership.

Earnings and Valuation

This table compares Cipher Pharmaceuticals and Acerus Pharmaceuticals' top-line revenue, earnings per share and valuation.

Cipher Pharmaceuticals has higher revenue and earnings than Acerus Pharmaceuticals. Acerus Pharmaceuticals is trading at a lower price-to-earnings ratio than Cipher Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Cipher Pharmaceuticals and Acerus Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of current ratings for Cipher Pharmaceuticals and Acerus Pharmaceuticals, as reported by MarketBeat.com.

Summary

Cipher Pharmaceuticals beats Acerus Pharmaceuticals on 5 of the 6 factors compared between the two stocks.

Cipher Pharmaceuticals (TSE:CPH) and Delta 9 Cannabis (CVE:NINE) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, dividends, risk and institutional ownership.

Earnings and Valuation

This table compares Cipher Pharmaceuticals and Delta 9 Cannabis' top-line revenue, earnings per share and valuation.

Cipher Pharmaceuticals has higher revenue and earnings than Delta 9 Cannabis. Cipher Pharmaceuticals is trading at a lower price-to-earnings ratio than Delta 9 Cannabis, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Cipher Pharmaceuticals and Delta 9 Cannabis' net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of current ratings for Cipher Pharmaceuticals and Delta 9 Cannabis, as reported by MarketBeat.com.

Summary

Cipher Pharmaceuticals beats Delta 9 Cannabis on 4 of the 6 factors compared between the two stocks.

Cipher Pharmaceuticals (TSE:CPH) and The Flowr (CVE:FLWR) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, dividends, risk and institutional ownership.

Earnings and Valuation

This table compares Cipher Pharmaceuticals and The Flowr's top-line revenue, earnings per share and valuation.

Cipher Pharmaceuticals has higher revenue and earnings than The Flowr. The Flowr is trading at a lower price-to-earnings ratio than Cipher Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Cipher Pharmaceuticals and The Flowr's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of current ratings for Cipher Pharmaceuticals and The Flowr, as reported by MarketBeat.com.

The Flowr has a consensus target price of C$0.70, suggesting a potential upside of 122.22%. Given The Flowr's higher probable upside, analysts clearly believe The Flowr is more favorable than Cipher Pharmaceuticals.

Summary

Cipher Pharmaceuticals beats The Flowr on 5 of the 7 factors compared between the two stocks.

Cipher Pharmaceuticals (TSE:CPH) and BioSyent (CVE:RX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, dividends, risk and institutional ownership.

Earnings and Valuation

This table compares Cipher Pharmaceuticals and BioSyent's top-line revenue, earnings per share and valuation.

Cipher Pharmaceuticals has higher earnings, but lower revenue than BioSyent. Cipher Pharmaceuticals is trading at a lower price-to-earnings ratio than BioSyent, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Cipher Pharmaceuticals and BioSyent's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of current ratings for Cipher Pharmaceuticals and BioSyent, as reported by MarketBeat.com.

BioSyent has a consensus target price of C$7.00, suggesting a potential downside of 11.39%. Given BioSyent's higher probable upside, analysts clearly believe BioSyent is more favorable than Cipher Pharmaceuticals.

Summary

BioSyent beats Cipher Pharmaceuticals on 5 of the 8 factors compared between the two stocks.

Cipher Pharmaceuticals (TSE:CPH) and Medexus Pharmaceuticals (CVE:MDP) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, dividends, risk and institutional ownership.

Earnings and Valuation

This table compares Cipher Pharmaceuticals and Medexus Pharmaceuticals' top-line revenue, earnings per share and valuation.

Cipher Pharmaceuticals has higher earnings, but lower revenue than Medexus Pharmaceuticals. Medexus Pharmaceuticals is trading at a lower price-to-earnings ratio than Cipher Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Cipher Pharmaceuticals and Medexus Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of current ratings for Cipher Pharmaceuticals and Medexus Pharmaceuticals, as reported by MarketBeat.com.

Summary

Cipher Pharmaceuticals beats Medexus Pharmaceuticals on 4 of the 7 factors compared between the two stocks.